Fresenius SE & Co. KGaA Logo

Fresenius SE & Co. KGaA

FRE.DE

(2.5)
Stock Price

33,85 EUR

0.48% ROA

-2.98% ROE

57.25x PER

Market Cap.

15.566.782.794,00 EUR

75.45% DER

3.3% Yield

-1.87% NPM

Fresenius SE & Co. KGaA Stock Analysis

Fresenius SE & Co. KGaA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Fresenius SE & Co. KGaA Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.73x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

4 ROE

The stock's ROE falls within an average range (4.86%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (2.43%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

7 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (843) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 DER

The stock is burdened with a heavy load of debt (140%), making it financially unstable and potentially risky for investors.

9 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

10 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Fresenius SE & Co. KGaA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Fresenius SE & Co. KGaA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Fresenius SE & Co. KGaA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Fresenius SE & Co. KGaA Revenue
Year Revenue Growth
2002 7.507.000.000
2003 7.064.000.000 -6.27%
2004 7.271.000.000 2.85%
2005 7.889.000.000 7.83%
2006 10.777.000.000 26.8%
2007 11.358.000.000 5.12%
2008 12.336.000.000 7.93%
2009 14.164.000.000 12.91%
2010 15.972.000.000 11.32%
2011 16.522.000.000 3.33%
2012 19.290.000.000 14.35%
2013 20.331.000.000 5.12%
2014 23.231.000.000 12.48%
2015 27.626.000.000 15.91%
2016 29.083.000.000 5.01%
2017 33.886.000.000 14.17%
2018 33.530.000.000 -1.06%
2019 35.409.000.000 5.31%
2020 36.277.000.000 2.39%
2021 37.520.000.000 3.31%
2022 40.840.000.000 8.13%
2023 22.072.000.000 -85.03%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Fresenius SE & Co. KGaA Research and Development Expenses
Year Research and Development Expenses Growth
2002 138.000.000
2003 121.000.000 -14.05%
2004 -133.000.000 190.98%
2005 -149.000.000 10.74%
2006 -167.000.000 10.78%
2007 -184.000.000 9.24%
2008 479.000.000 138.41%
2009 240.000.000 -99.58%
2010 244.000.000 1.64%
2011 267.000.000 8.61%
2012 305.000.000 12.46%
2013 348.000.000 12.36%
2014 369.000.000 5.69%
2015 464.000.000 20.47%
2016 500.000.000 7.2%
2017 558.000.000 10.39%
2018 673.000.000 17.09%
2019 645.000.000 -4.34%
2020 751.000.000 14.11%
2021 805.000.000 6.71%
2022 867.000.000 7.15%
2023 680.000.000 -27.5%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Fresenius SE & Co. KGaA General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 1.461.000.000
2003 1.374.000.000 -6.33%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.972.000.000 100%
2009 2.342.000.000 15.8%
2010 2.664.000.000 12.09%
2011 2.809.000.000 5.16%
2012 2.254.000.000 -24.62%
2013 2.243.000.000 -0.49%
2014 2.518.000.000 10.92%
2015 3.280.000.000 23.23%
2016 3.385.000.000 3.1%
2017 4.591.000.000 26.27%
2018 3.857.000.000 -19.03%
2019 4.386.000.000 12.06%
2020 4.373.000.000 -0.3%
2021 4.394.000.000 0.48%
2022 5.524.000.000 20.46%
2023 3.024.000.000 -82.67%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Fresenius SE & Co. KGaA EBITDA
Year EBITDA Growth
2002 677.000.000
2003 663.000.000 -2.11%
2004 483.000.000 -37.27%
2005 542.000.000 10.89%
2006 729.000.000 25.65%
2007 831.000.000 12.27%
2008 1.949.000.000 57.36%
2009 2.607.000.000 25.24%
2010 3.021.000.000 13.7%
2011 3.193.000.000 5.39%
2012 3.081.000.000 -3.64%
2013 3.157.000.000 2.41%
2014 3.434.000.000 8.07%
2015 4.306.000.000 20.25%
2016 4.495.000.000 4.2%
2017 5.004.000.000 10.17%
2018 5.349.000.000 6.45%
2019 7.216.000.000 25.87%
2020 7.162.000.000 -0.75%
2021 6.949.000.000 -3.07%
2022 6.481.000.000 -7.22%
2023 1.384.000.000 -368.28%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Fresenius SE & Co. KGaA Gross Profit
Year Gross Profit Growth
2002 2.436.000.000
2003 2.276.000.000 -7.03%
2004 2.376.000.000 4.21%
2005 2.589.000.000 8.23%
2006 3.426.000.000 24.43%
2007 3.678.000.000 6.85%
2008 3.928.000.000 6.36%
2009 4.638.000.000 15.31%
2010 5.326.000.000 12.92%
2011 5.639.000.000 5.55%
2012 6.288.000.000 10.32%
2013 6.383.000.000 1.49%
2014 6.842.000.000 6.71%
2015 8.534.000.000 19.83%
2016 9.128.000.000 6.51%
2017 10.476.000.000 12.87%
2018 9.834.000.000 -6.53%
2019 10.348.000.000 4.97%
2020 10.316.000.000 -0.31%
2021 10.311.000.000 -0.05%
2022 10.725.000.000 3.86%
2023 5.088.000.000 -110.79%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Fresenius SE & Co. KGaA Net Profit
Year Net Profit Growth
2002 134.000.000
2003 115.000.000 -16.52%
2004 168.000.000 31.55%
2005 222.000.000 24.32%
2006 330.000.000 32.73%
2007 410.000.000 19.51%
2008 270.000.000 -51.85%
2009 991.000.000 72.75%
2010 1.205.000.000 17.76%
2011 1.328.000.000 9.26%
2012 926.000.000 -43.41%
2013 1.011.000.000 8.41%
2014 1.067.000.000 5.25%
2015 1.358.000.000 21.43%
2016 1.593.000.000 14.75%
2017 1.814.000.000 12.18%
2018 2.027.000.000 10.51%
2019 1.883.000.000 -7.65%
2020 1.707.000.000 -10.31%
2021 1.818.000.000 6.11%
2022 1.372.000.000 -32.51%
2023 -1.624.000.000 184.48%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Fresenius SE & Co. KGaA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 1
2003 1 0%
2004 1 100%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 1 100%
2010 1 0%
2011 1 0%
2012 2 0%
2013 2 0%
2014 2 0%
2015 3 50%
2016 3 0%
2017 3 33.33%
2018 4 0%
2019 3 0%
2020 3 0%
2021 3 0%
2022 2 -50%
2023 -3 200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Fresenius SE & Co. KGaA Free Cashflow
Year Free Cashflow Growth
2002 320.000.000
2003 437.000.000 26.77%
2004 851.000.000 48.65%
2005 780.000.000 -9.1%
2006 1.052.000.000 25.86%
2007 1.296.000.000 18.83%
2008 315.000.000 -311.43%
2009 640.000.000 50.78%
2010 1.157.000.000 44.68%
2011 906.000.000 -27.7%
2012 1.468.000.000 38.28%
2013 1.249.000.000 -17.53%
2014 1.240.000.000 -0.73%
2015 1.838.000.000 32.54%
2016 1.946.000.000 5.55%
2017 -4.175.000.000 146.61%
2018 523.000.000 898.28%
2019 1.804.000.000 71.01%
2020 4.143.000.000 56.46%
2021 3.031.000.000 -36.69%
2022 2.281.000.000 -32.88%
2023 1.327.000.000 -71.89%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Fresenius SE & Co. KGaA Operating Cashflow
Year Operating Cashflow Growth
2002 697.000.000
2003 776.000.000 10.18%
2004 851.000.000 8.81%
2005 780.000.000 -9.1%
2006 1.052.000.000 25.86%
2007 1.296.000.000 18.83%
2008 1.074.000.000 -20.67%
2009 1.553.000.000 30.84%
2010 1.911.000.000 18.73%
2011 1.689.000.000 -13.14%
2012 2.438.000.000 30.72%
2013 2.320.000.000 -5.09%
2014 2.585.000.000 10.25%
2015 3.327.000.000 22.3%
2016 3.574.000.000 6.91%
2017 3.937.000.000 9.22%
2018 3.742.000.000 -5.21%
2019 4.263.000.000 12.22%
2020 6.549.000.000 34.91%
2021 5.078.000.000 -28.97%
2022 4.198.000.000 -20.96%
2023 1.408.000.000 -198.15%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Fresenius SE & Co. KGaA Capital Expenditure
Year Capital Expenditure Growth
2002 377.000.000
2003 339.000.000 -11.21%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 759.000.000 100%
2009 913.000.000 16.87%
2010 754.000.000 -21.09%
2011 783.000.000 3.7%
2012 970.000.000 19.28%
2013 1.071.000.000 9.43%
2014 1.345.000.000 20.37%
2015 1.489.000.000 9.67%
2016 1.628.000.000 8.54%
2017 8.112.000.000 79.93%
2018 3.219.000.000 -152%
2019 2.459.000.000 -30.91%
2020 2.406.000.000 -2.2%
2021 2.047.000.000 -17.54%
2022 1.917.000.000 -6.78%
2023 81.000.000 -2266.67%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Fresenius SE & Co. KGaA Equity
Year Equity Growth
2002 -155.000.000
2003 -142.000.000 -9.15%
2004 1.603.000.000 108.86%
2005 2.776.000.000 42.26%
2006 3.102.000.000 10.51%
2007 3.338.000.000 7.07%
2008 3.910.000.000 14.63%
2009 4.270.000.000 8.43%
2010 4.965.000.000 14%
2011 5.971.000.000 16.85%
2012 7.633.000.000 21.77%
2013 8.195.000.000 6.86%
2014 9.335.000.000 12.21%
2015 10.935.000.000 14.63%
2016 12.503.000.000 12.54%
2017 13.661.000.000 8.48%
2018 25.008.000.000 45.37%
2019 26.580.000.000 5.91%
2020 26.023.000.000 -2.14%
2021 29.288.000.000 11.15%
2022 32.218.000.000 9.09%
2023 30.282.000.000 -6.39%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Fresenius SE & Co. KGaA Assets
Year Assets Growth
2002 8.915.000.000
2003 8.347.000.000 -6.8%
2004 8.188.000.256 -1.94%
2005 11.594.000.384 29.38%
2006 15.024.000.000 22.83%
2007 15.324.000.256 1.96%
2008 20.544.000.000 25.41%
2009 20.882.000.000 1.62%
2010 23.577.000.000 11.43%
2011 26.321.000.000 10.43%
2012 30.664.000.000 14.16%
2013 32.758.000.000 6.39%
2014 39.897.000.000 17.89%
2015 43.170.000.000 7.58%
2016 46.447.000.000 7.06%
2017 53.133.000.000 12.58%
2018 56.703.000.000 6.3%
2019 67.006.000.000 15.38%
2020 66.646.000.000 -0.54%
2021 71.962.000.000 7.39%
2022 76.415.000.000 5.83%
2023 75.328.000.000 -1.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Fresenius SE & Co. KGaA Liabilities
Year Liabilities Growth
2002 5.546.000.000
2003 5.133.000.000 -8.05%
2004 6.585.000.256 22.05%
2005 8.818.000.384 25.32%
2006 11.922.000.000 26.04%
2007 11.986.000.256 0.53%
2008 13.601.000.000 11.87%
2009 13.230.000.000 -2.8%
2010 14.733.000.000 10.2%
2011 15.744.000.000 6.42%
2012 17.508.000.000 10.08%
2013 19.026.000.000 7.98%
2014 23.733.000.000 19.83%
2015 24.220.000.000 2.01%
2016 24.843.000.000 2.51%
2017 31.413.000.000 20.91%
2018 31.695.000.000 0.89%
2019 40.426.000.000 21.6%
2020 40.623.000.000 0.48%
2021 42.674.000.000 4.81%
2022 44.197.000.000 3.45%
2023 45.046.000.000 1.88%

Fresenius SE & Co. KGaA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
65.16
Net Income per Share
0.49
Price to Earning Ratio
57.25x
Price To Sales Ratio
0.42x
POCF Ratio
3.43
PFCF Ratio
5.36
Price to Book Ratio
0.79
EV to Sales
0.81
EV Over EBITDA
6.18
EV to Operating CashFlow
6.44
EV to FreeCashFlow
10.19
Earnings Yield
0.02
FreeCashFlow Yield
0.19
Market Cap
15,57 Bil.
Enterprise Value
29,59 Bil.
Graham Number
19.74
Graham NetNet
-25.46

Income Statement Metrics

Net Income per Share
0.49
Income Quality
5.35
ROE
0.01
Return On Assets
-0.01
Return On Capital Employed
0.05
Net Income per EBT
-0.51
EBT Per Ebit
0.66
Ebit per Revenue
0.06
Effective Tax Rate
0.52

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.23
Operating Profit Margin
0.06
Pretax Profit Margin
0.04
Net Profit Margin
-0.02

Dividends

Dividend Yield
0.03
Dividend Yield %
3.3
Payout Ratio
4.72
Dividend Per Share
0.92

Operating Metrics

Operating Cashflow per Share
8.15
Free CashFlow per Share
5.15
Capex to Operating CashFlow
-0.37
Capex to Revenue
-0.05
Capex to Depreciation
-1
Return on Invested Capital
0.05
Return on Tangible Assets
0
Days Sales Outstanding
374.3
Days Payables Outstanding
15.95
Days of Inventory on Hand
34.91
Receivables Turnover
0.98
Payables Turnover
22.88
Inventory Turnover
10.46
Capex per Share
-2.99

Balance Sheet

Cash per Share
1,94
Book Value per Share
35,53
Tangible Book Value per Share
21.09
Shareholders Equity per Share
35.53
Interest Debt per Share
28.14
Debt to Equity
0.75
Debt to Assets
0.2
Net Debt to EBITDA
2.93
Current Ratio
1.54
Tangible Asset Value
11,89 Bil.
Net Current Asset Value
-0,21 Bil.
Invested Capital
0.75
Working Capital
15,65 Bil.
Intangibles to Total Assets
0.24
Average Receivables
22,72 Bil.
Average Payables
1,57 Bil.
Average Inventory
3840500000
Debt to Market Cap
0.97

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Fresenius SE & Co. KGaA Dividends
Year Dividends Growth
2000 2
2001 0 0%
2002 1 100%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 100%
2014 1 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 2 100%
2021 1 0%
2022 1 0%
2023 1 0%

Fresenius SE & Co. KGaA Profile

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

CEO
Mr. Michael Sen
Employee
193.865
Address
Else-Kroener-Strasse 1
Bad Homburg vor der Höhe, 61352

Fresenius SE & Co. KGaA Executives & BODs

Fresenius SE & Co. KGaA Executives & BODs
# Name Age
1 Mr. Robert Moller
Member of the Management Board of Fresenius Management SE
70
2 Dr. Michael Sven Moser Ph.D.
Member of Management Board of Fresenius Management SE
70
3 Matthias Link
Senior Vice President Corporate Communications
70
4 Mr. Michael Sen
Chief Executive Officer, President & Chairman of Management Board - Fresenius Management SE
70
5 Ms. Sara Lisa Hennicken
Chief Financial Officer & Member of the Management Board - Fresenius Management SE
70
6 Mr. Pierluigi Antonelli
Member of Management Board of Fresenius Management SE & Chief Executive Officer of Fresenius Kabi
70
7 Mr. Markus Georgi
Senior Vice President of Investor Relations
70

Fresenius SE & Co. KGaA Competitors